BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33848944)

  • 1. Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity.
    Mahajan M; Suryavanshi S; Bhowmick S; Alasmary FA; Almutairi TM; Islam MA; Kaul-Ghanekar R
    Biophys Chem; 2021 Jun; 273():106588. PubMed ID: 33848944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polyherbal formulation, HC9 regulated cell growth and expression of cell cycle and chromatin modulatory proteins in breast cancer cell lines.
    Suryavanshi S; Choudhari A; Raina P; Kaul-Ghanekar R
    J Ethnopharmacol; 2019 Oct; 242():112022. PubMed ID: 31201865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
    Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
    Heimburg T; Kolbinger FR; Zeyen P; Ghazy E; Herp D; Schmidtkunz K; Melesina J; Shaik TB; Erdmann F; Schmidt M; Romier C; Robaa D; Witt O; Oehme I; Jung M; Sippl W
    J Med Chem; 2017 Dec; 60(24):10188-10204. PubMed ID: 29190092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
    Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
    Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selenocoumarins as new multitarget antiproliferative agents: Synthesis, biological evaluation and in silico calculations.
    Lagunes I; Begines P; Silva A; Galán AR; Puerta A; Fernandes MX; Maya I; Fernández-Bolaños JG; López Ó; Padrón JM
    Eur J Med Chem; 2019 Oct; 179():493-501. PubMed ID: 31271961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
    Adhikari N; Amin SA; Jha T
    Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
    Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
    Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells.
    Martínez-Ramos F; Luna-Palencia GR; Vásquez-Moctezuma I; Méndez-Luna D; Fragoso-Vázquez MJ; Trujillo-Ferrara J; Meraz-Ríos MA; Mendieta-Wejebe JE; Correa-Basurto J
    Anticancer Agents Med Chem; 2016; 16(11):1485-1490. PubMed ID: 26845132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.
    Liu J; Zhou J; He F; Gao L; Wen Y; Gao L; Wang P; Kang D; Hu L
    Eur J Med Chem; 2020 Apr; 192():112189. PubMed ID: 32151834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study.
    Yao P; Gao Q; Wang Y; Yao Q; Zhang J
    ChemMedChem; 2021 Jun; 16(12):1933-1944. PubMed ID: 33686739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Histone Deacetylase 8 Inhibitor through Drug Screenings Based on Machine Learning.
    Nurani A; Yamashita Y; Taki Y; Takada Y; Itoh Y; Suzuki T
    Chem Pharm Bull (Tokyo); 2024; 72(2):173-178. PubMed ID: 38296560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.
    Thangapandian S; John S; Sakkiah S; Lee KW
    Eur J Med Chem; 2010 Oct; 45(10):4409-17. PubMed ID: 20656379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.